Benefit of Apabetalone on Plasma Proteins in Renal Disease-Reference-Cited by-同舟云学术

Benefit of Apabetalone on Plasma Proteins in Renal Disease

Published:2018-05 Issue:3 Volume:3 Page:711-721
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Wasiak Sylwia,Tsujikawa Laura M.,Halliday Christopher,Stotz Stephanie C.,Gilham Dean,Jahagirdar Ravi,Kalantar-Zadeh Kamyar,Robson Richard,Sweeney Michael,Johansson Jan O.,Wong Norman C.,Kulikowski Ewelina

Publisher

Elsevier BV

Subject

Nephrology

Reference71 articles.

1. A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010;Mills;Kidney Int,2015

2. Cardiovascular co-morbidity in chronic kidney disease: current knowledge and future research needs;Alani;World J Nephrol,2014

3. The systemic nature of CKD;Zoccali;Nat Rev Nephrol,2017

4. Current epigenetic aspects the clinical kidney researcher should embrace;Witasp;Clin Sci (Lond),2017

5. Epigenetics of progression of chronic kidney disease: fact or fantasy?;Wing;Semin Nephrol,2013

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the therapeutic potential of apabetalone in diabetic kidney disease: Bridging preclinical findings with clinical translation;Pharmacological Research;2024-10

2. BRD4: an effective target for organ fibrosis;Biomarker Research;2024-08-30

3. Epigenetic modulation through BET bromodomain inhibitors as a novel therapeutic strategy for progranulin-deficient frontotemporal dementia;Scientific Reports;2024-04-20

4. Lipoprotein dysfunction in patients with chronic kidney disease (CKD). Pathogenesis and treatment of CKD dyslipidemia (literature review);Nephrology (Saint-Petersburg);2024-03-03

5. Apabetalone (RVX-208): A Potential Epigenetic Therapy for the Treatment of Cardiovascular, Renal, Neurological, Viral, and Cancer Disorders;ACS Pharmacology & Translational Science;2024-02-06